Table I.
Incidence of IRAEs during anticancer immunotherapy with anti-CTLA4 or anti-PD1/PD-L1 antibodies.
| IRAE incidence (all grades), % | ||
|---|---|---|
| IRAEs | Anti-CTLA4 immunotherapy | Anti-PD1/PD-L1 immunotherapy |
| Dermatological (rash, pruritus, psoriasiform eruptions, vitiligo, Sweet's syndrome, Stevens-Johnson syndrome, toxic epidermal necrosis, pyoderma gangrenosum, cutaneous sarcoidosis) | 44.0 | 37.4 |
| Gastrointestinal (diarrhea, colitis, hepatitis, pancreatitis) | 30.0 | 20.0 |
| Fatigue | 46.0 | 47.0 |
| Endocrine (thyroid dysfunction, hypophysitis, adrenal insufficiency) | 10.0 | <10.0 |
| Musculoskeletal | 6.1 | 7.6 |
| Mucosal toxicity (oral mucositis, dry mouth) | <5.0 | 5.0 |
| Respiratory (pulmonitis) | 1.0 | <1.0 |
| Ophthalmological (episcleritis, conjunctivitis, uveitis, orbital inflammation) | <1.0 | – |
| Neurological (paresthesia, Guillain-Barré syndrome, aseptic or lymphocytic meningitis, posterior reversible encephalopathy syndrome, inflammatory enteric neuropathy, transverse myelitis) | <1.0 | – |
| Renal (renal failure) | <1.0 | 1.0–22.0 |
| Hematological (red cell aplasia, autoimmune neutropenia or pancytopenia, acquired hemophilia) | <1.0 | – |
IRAE, immune-related adverse event; CTLA4, cytotoxic T lymphocyte antigen 4; PD1, programmed cell death protein 1; PD-L1, programmed death ligand 1.